Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Co.'s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. Co. is evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial; and RLYB116, a subcutaneously administered inhibitor of complement factor 5. The RLYB YTD return is shown above.
The YTD Return on the RLYB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether RLYB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RLYB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|